Fig. 1From: RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trialTrial flow chart. D1 day 1, D2 day 2, D8 day 8, R rituximab, V varlilumabBack to article page